Catégorie : Nouvelles

Un enfant de 12 ans publie un livre pour enfants sur la maladie de Huntington

Toronto student writes book so others will treat her grandpa kindly December 11, 2024 — Toronto, Ontario, Canada Most people have never heard of Huntington’s disease. This lack of awareness […]

UniQure annonce un alignement avec la FDA sur les éléments clés de la voie d'homologation accélérée de l'AMT-130

Yesterday, uniQure issued a press release announcing alignment with the US Food and Drug Administration (FDA) on key elements of an accelerated approval pathway for uniQure‘s AMT-130 program in Huntington’s […]

Le documentaire "The Present" de Dimitri Poffé est désormais disponible sur Youtube.

Dimitri Poffé is an already known member of the HD Community. After testing positive for Huntington’s Disease, Dimitri embraced a bicycle journey through South America. In this project, called Explore […]

PTC Therapeutics conclut un accord mondial de licence et de collaboration avec Novartis pour le programme PTC518 sur la maladie de Huntington

December 2, 2024 – PTC to receive $1.0B in cash at closing –– PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones –– PTC to share profits in the U.S. and […]

Sage Therapeutics arrête le développement du dalzanemdor dans la maladie de Huntington

The Phase 2 DIMENSION Study did not meet its primary endpoint Dalzanemdor was generally well-tolerated; no new safety signals were observed Based on these data, the Company does not plan […]

Le pouvoir du partenariat. La Suisse et la Chine donnent l'exemple.

In this video, Professor Jean-Marc Burgunder, head of the Huntington’s Disease (HD) centre in Bern Switzerland, and Xi Cao, President of the Chinese HD Association talk about the benefits of […]

Livable Lives - un nouveau livre qui présente des histoires de personnes touchées par la maladie de Parkinson dans le monde entier.

COMMUNIQUÉ DE PRESSE - 25 octobre 2024, Moscou, Idaho, États-UnisNous avons le plaisir d'annoncer le lancement d'un nouveau livre sur la maladie de Huntington (MH) intitulé Livable Lives : Conversations with the Huntington's [...]

LoQus23 Therapeutics annonce un financement de 35 millions de livres sterling pour faire progresser un nouveau médicament visant à inhiber l'expansion somatique dans la maladie de Huntington.

Cambridge, UK, 2 October 2024 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop DNA instability and slow neurodegeneration in Huntington’s Disease, myotonic dystrophy […]

La FDA accorde la désignation Fast Track au programme PTC518 sur la maladie de Huntington

PTC518 is an oral medication that reduces the production of the mutated Huntingtin protein that causes disease progression.   Programs with Fast Track designation can benefit from early interactions with the FDA, and may be […]

La Pridopidine de Prilenia pour la maladie de Huntington acceptée pour l'examen de l'autorisation de mise sur le marché européen

Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing […]